PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项为期5年的研究，旨在评估聚乙二醇化干扰素联合或不联合利巴韦林治疗6-18岁儿童丙型肝炎的效果。副作用，对生长，体重和心理状况的影响以及生活方式的改变也通过辅助研究进行监测。这项研究由美国国立卫生研究院资助，部分由罗氏制药公司资助。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a five year study to assess the effect of treatment of Hepatitis C with pegylated interferon with or without ribavirin in children between ages 6-18. The side effects , effects on growth, weight and psychological profile and life style changes are also monitored through ancillary studies. The study is funded by the NIH and in part by Roche Pharmacueticals.